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Background: Extraintestinal manifestations (EIMs) in patients with inﬂammatory bowel disease (IBD) are frequently observed. Little is known about
the efﬁcacy of anti–tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (inﬂiximab, adalimumab, and
certolizumab pegol) on EIM evolution.
Methods: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists.
Response was classiﬁed into improvement, stable disease, and clinical worsening based on the physician’s interpretation.
Results: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs.
Patients with EIM were signiﬁcantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P , 0.001). Inﬂiximab
was the most frequently used drug (63.2%). In more than 71.8%, a clinical response of the underlying EIM to anti-TNF therapy was observed. In 92
patients (43.2%), anti-TNF treatments were started for the purpose of treating EIM rather than IBD. Response rates to anti-TNF were generally good and
best for psoriasis, aphthous stomatitis, uveitis, and peripheral arthritis. In 11 patients, 14 EIM occurred under anti-TNF treatment.
Conclusions: Anti-TNF was frequently used among patients with EIM. In more than 40%, anti-TNF treatments are started to treat EIM rather than IBD.
Given the good response rates, anti-TNF seems to be a valuable option in the treatment of EIM, whereas appearance of EIM under anti-TNF does not
seem to be a source of considerable concern.
(Inﬂamm Bowel Dis 2017;23:1174–1181)
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I nﬂammatory bowel diseases (IBD) with the 2 main subtypes,Crohn’s disease (CD) and ulcerative colitis (UC), are chronic
inﬂammatory disorders of the gastrointestinal tract. The etiopatho-
genesis of IBD is incompletely understood, although it is consid-
ered to be a multifactorial disease, which arises from a complex
interplay between genetic, environmental, and immunological
factors with an abnormal host immune response to environmental
stimuli.1,2 Extraintestinal manifestations (EIMs) of IBD are
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frequently observed with a prevalence ranging from 6% to
47%.3–10 EIMs considerably affect morbidity and mortality in
patients with IBD.11,12 EIMs mostly affect joints (peripheral
arthritis, axial arthropathy [AS]), the skin (erythema nodosum
[EN], pyoderma gangrenosum [PG]), the eyes (uveitis), and the
hepatobiliary tract (primary sclerosing cholangitis [PSC]).
Although some EIMs are associated with IBD activity such as type
1 arthritis or EN, other EIMs such as PG, AS, uveitis, PSC, or type
2 arthritis do not parallel intestinal disease activity.10,13–16 Although
different EIMs tend to cluster in up to one quarter of EIM-affected
patients, suggesting a common pathogenic link, little is known
about their underlying pathomechanisms.11,17 However, both intes-
tinal and extraintestinal IBD manifestations are believed to share
tumor necrosis factor (TNF)-dependent mechanisms.18
There is limited evidence regarding the efﬁcacy of particular
EIM treatments. This lack of good evidence is probably related to
the difﬁculty of analyzing EIM treatments in a cross-sectional
manner as only a few patients will suffer from EIM at the time of
study enrollment.18 Although introduction of biologics considerably
changed the management of EIM in IBD, there are only few and
small studies supporting evidence for the efﬁcacy of anti-TNF:
Inﬂiximab may be efﬁcacious in cutaneous, ocular, and joint man-
ifestations with clinical response for PG, EN, aphthous
stomatitis,19–24 and peripheral arthritis and AS, respectively.19,21,25
The strongest evidence for efﬁcacy of inﬂiximab has been shown in
PG management.26 In addition, there is some evidence for the efﬁ-
cacy of adalimumab in patients with CD presenting with EIM.27
The CARE study (Crohn’s Treatment with Adalimumab: Patient
Response to a Safety and Efﬁcacy Study), an open label multicenter
phase IIIb trial showed a signiﬁcant decrease in the frequency of
arthralgia, arthritis, oral aphthous ulcers, and EN at week 20.28 In
contrast, anti-TNF treatment for PSC is not recommended given the
lack of evidence for clinical efﬁcacy. If anti-TNF has to be used for
underlying IBD activity, the course of PSC is inﬂuenced neither
positively nor negatively.29,30 Current (limited) knowledge on anti-
TNF efﬁcacy has been nicely summarized by Peyrin-Biroulet et al
recently.31 However, because of signiﬁcant variations between the
analyzed studies (regarding study design, studied EIM, and study
outcome) data have not been meta-analyzed.
Given this limited evidence for efﬁcacy of anti-TNF
treatment in IBD patients with EIM, we investigated the role of
anti-TNF agents in the large nation-wide Swiss IBD Cohort Study
(SIBDCS) and analyzed the inﬂuence of 3 available anti-TNF
agents (inﬂiximab, adalimumab, and certolizumab pegol) on the
evolution of different EIMs.
METHODS
Patients
The SIBDCS is a nation-wide cohort study from all regions of
Switzerland, which has been including patients with IBD meeting the
diagnostic criteria according to the established guidelines. Enrollment
started in 2006. The SIBDCS is supported by the Swiss National
Science Foundation and is approved by the local ethics committees
of the participating centers. The patients have to meet the following
inclusion criteria: (1) written informed consent, (2) permanent
residency status in Switzerland and/or coverage by a Swiss health
insurance, (3) diagnosis of CD, UC, or IBD unclassiﬁed established
at least 4 months before enrollment or at least 1 episode of symptom
recurrence. Assessment includes a thorough clinical and laboratory
analyses (including information about IBD diagnosis, clinical course,
disease activity, surgery, medication, and EIM). A detailed ques-
tionnaire about IBD diagnosis, clinical course, and disease activity is
completed by patients’ treating physicians. Patient-reported outcome
questionnaires are completed by each individual patient. Annual
follow-up questionnaires are completed by both the responsible
physicians and their patients.
Deﬁnition of EIM and Anti-TNF Outcome
All EIMs had to be diagnosed by a relevant specialist:
Diagnosis of skin manifestations was established by a dermatol-
ogist, of joint affections by a rheumatologist, of eye manifes-
tations by an ophthalmologist, and of PSC by a gastroenterologist.
We analyzed the following EIM: peripheral arthritis, uveitis, PG,
EN, aphthous stomatitis, AS, psoriasis, and PSC. Diagnosis of
EIM relied on previously published criteria.17 Evolution of EIM
under anti-TNF treatment was judged according to the relevant
specialist’s global assessment that was based on patient history,
clinical ﬁndings, and laboratory parameters (in the case of PSC).
The course of a particular EIM under anti-TNF treatment was
classiﬁed into the following 3 categories: clinical improvement,
stable disease unaffected by anti-TNF, and clinical worsening.
Data Collection and Management
Data were entered into a Microsoft Access database
(Access 2000; Microsoft Switzerland Ltd. Liab. Co., Wallisellen,
Switzerland). All completed questionnaires were sent to the data
center of the SIBDCS located at the Institute of Social and
Preventive Medicine, University of Lausanne, Switzerland. All
data were validated by the responsible data manager. Collected
data consisted of 2 standardized questionnaires, one completed by
the responsible physician, the other by each individual patient.
The former included the following items: demographic character-
istics, onset of symptoms, date of diagnosis, extent of disease,
IBD family history, smoking status, results of laboratory tests,
current therapy, and medical history. Furthermore, this question-
naire assessed past and present EIM. The latter questionnaire
completed by each patient included the following items: patient
demographics, IBD diagnosis, and current medications. Because
information about appearance of EIM in relation to the time of
IBD diagnosis and evolution of EIM under anti-TNF treatment
was not captured by those standardized questionnaires, we further
reviewed each individual’s patient chart at the responsible IBD
center to complete, together with the treating physician and the
relevant specialist, an additional questionnaire, which included
items on various characteristics of EIM and their evolution under
anti-TNF treatment. All 1249 patients with IBD who were
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enrolled into the SIBDCS between January 2006 and March 2010
were eligible for this study. For outcome analysis, only those
patients with both EIM and current or past anti-TNF treatment
were included. EIMs were only taken into account if present at the
time of anti-TNF treatment.
Statistical Analysis
For all statistical analyses, IBM software SPSS version
23.0.0 (2014 SPSS Science, Inc., Chicago, IL) was used. Metric
data are shown as medians with their total range. Categorical data
are summarized as the percentage of the group total. Comparisons
between categorical data were performed using Chi-square test, or
the Fisher’s exact test in case of small sample size (n , 10).
Multivariate logistic regression analysis regarding prediction of
anti-TNF response was performed by ﬁrst taking into account all
covariates with a univariate P value of ,0.15, removing insignif-
icant covariates, and then adding remaining covariates one by one,
checking the model signiﬁcance and consistency at each step. A
2-sided P value of ,0.05 was regarded as statistically signiﬁcant.
RESULTS
Patient Demographics
Of the 1249 patients who were enrolled into the SIBDCS
between January 2006 and March 2010, 366 (29.3%) suffered
from at least 1 EIM that occurred either before or after the time of
IBD diagnosis. Of those, 213 patients (58.2%) were ever treated
with one or several anti-TNF agents, whereas 153 (41.8%) had
never received these drugs. Patients with EIM were signiﬁcantly
TABLE 1. Demographic Data According to IBD Subtype
UC (n ¼ 40) CD (n ¼ 165) IBD-U (n ¼ 6) Total (n ¼ 213)
Sex
No. of males, n (%) 18 (45.0) 59 (35.8) 0 (0) 77 (36.2)
Age at IBD diagnosis 29.0 (13.8–61.5) 24.5 (4.0–58.7) 28.3 (18.3–36.8) 25.2 (4.0–61.5)
Age at enrollment 30.4 (20.4–64.8) 39.6 (16.1–73.8) 32.5 (20.6–44.7) 39.2 (16.1–73.8)
Duration of IBD at enrollment 9.9 (0.3–20.2) 9.8 (0.3–36.6) 4.4 (0.8–7.4) 9.0 (0.3–36.6)
Disease location, n (%) E1: 2 (5.0) L1: 33 (20.0)
E2: 20 (50.0) L2: 53 (32.1)
E3: 13 (32.5) L3: 35 (21.2)
Missing: 5 (12.5) L4: 2 (1.2)
L1+L4: 1 (0.6)
L2+L4: 1 (0.6)
L3+L4: 2 (1.2)
Missing: 38 (23.0)
Cohort follow-up time, mo 81.6 (0.0–102.0) 83.7 (0.0–108.0) 87.8 (60.7–97.2) 83.7 (0.0–108.0)
Previous medication, n (%)
5-ASA 37 (92.5) 107 (64.8) 6 (100.0) 152 (71.4)
AB 19 (47.5) 103 (62.4) 4 (66.7) 128 (60.1)
Steroids 39 (97.5) 156 (94.5) 6 (100.0) 203 (95.3)
IM 35 (87.5) 158 (95.8) 6 (100.0) 201 (94.4)
Comedication concomitant with anti-TNF, n (%)
5-ASA 12 (30.0) 22 (13.3) 1 (16.7) 35 (16.4)
AB 0 (0.0) 15 (9.1) 0 (0.0) 15 (7.0)
Steroids 19 (47.5) 52 (31.5) 3 (50.0) 75 (35.2)
IM 5 (12.5) 52 (31.5) 4 (66.7) 61 (28.6)
Smoking status, n (%)
No 37 (92.5) 101 (61.2) 4 (66.7) 142 (66.7)
Yes 2 (5.0) 61 (37.0) 2 (33.3) 67 (31.5)
unknown 1 (2.5) 3 (1.8) 0 (0.0) 4 (1.9)
IBD subtype of 2 patients unknown. Disease location L1 (disease isolated to ileum), L2 (disease isolated to large bowel), L3 (disease involving ileum and colon), L4 (disease isolated to
upper gastrointestinal tract), E1 (proctitis, inﬂammation limited to the rectum), E2 (left-sided distal, inﬂammation limited to the splenic ﬂexure), E3 (pancolitis, inﬂammation extends to
the proximal splenic ﬂexure).
5-ASA, 5-aminosalicylic acid;AB, antibiotics; IBD-U, IBD unclassiﬁed; IM, immunomodulators (methotrexate, azathioprine, and cyclosporine).
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more often treated with anti-TNF compared with those patients
without EIM (213/366, 58.2% versus 185/883, 21.0%, P ,
0.001). Seventy-seven patients of those 213 treated with anti-
TNF were men (36.2%), 40 patients had UC (18.8%), 165 had
CD (77.5%), and 6 had IBD unclassiﬁed (2.8%). In 2 patients,
exact IBD subtype was unclear or subtype classiﬁcation changed
over time. Median age at IBD diagnosis was 25.2 years (4.0–61.5)
with a median age of 39.2 years (16.1–73.8) at enrollment into the
SIBDCS. Median duration of IBD at enrollment was 9.0 years
(0.3–36.6). The clinical characteristics of these 213 patients are
summarized in Table 1 according to the underlying IBD subtype.
Frequency and Types of EIM
Most of the 213 patients included in our analysis suffered
from 1 EIM (122/213, 57.3%), whereas 30.5% of patients (65/
213) had 2 EIMs, 4.7% (10/213) had 3 EIMs, and 3.3% (7/213)
had 4 EIMs. The maximum number of EIMs was 5 (9/213, 4.2%).
The most frequently reported EIMs were peripheral arthritis (161/
213, 75.6%), aphthous stomatitis (50/213, 23.5%), and AS (46/
213, 21.6%). Median duration from IBD to EIM was 4.4 years
(217.7 to 34.2). A detailed overview over the different EIMs
according to IBD subtype is provided in Table 2.
Type of Anti-TNF Treatment and Treated EIM
in the Study Population
One hundred forty-seven patients (69.0%) were treated
with 1 TNF blocker, whereas in 46 patients 2 different TNF
blockers were initiated successively (21.6%) and in the remaining
20 patients (9.4%) a total of 3 anti-TNF courses were started.
Thus, a total of 299 anti-TNF therapies were initiated in these 213
patients with 355 EIM. Inﬂiximab was used in 63.2% (n ¼ 189),
adalimumab in 22.4% (n ¼ 67), and certolizumab pegol was used
in 14.4% (n ¼ 43). CD patients with EIM were signiﬁcantly more
frequently treated with anti-TNF compared with patients with UC
(165/248, 66.5% versus 40/105, 38.1%, P , 0.001). Anti-TNF
agents were started in 49.3% of patients (n ¼ 105) to treat intes-
tinal IBD activity, in 43.2% (n ¼ 92) of patients to treat EIM, and
in 0.5% (n ¼ 1) of patients to treat both intestinal activity and
EIM. In the remaining 15 patients (7.0%), the exact indication for
anti-TNF treatment could not be identiﬁed. In 224 of the 299 anti-
TNF treatments (74.9%), the underlying EIMs were recorded in
detail: Among the most frequently reported were peripheral arthri-
tis (158/224, 70.5%), aphthous stomatitis (32/224, 14.3%), AS
(34/224, 15.2%), and uveitis (25/224, 11.2%). Further treated
EIMs were PG (12/224, 5.4%), PSC (8/224, 3.6%), EN
(10/224, 4.5%), and psoriasis (6/224, 2.7%). Order of frequency
of treated EIM showed signiﬁcant differences when those patients
reporting EIM as an indication for anti-TNF treatment were com-
pared with those reporting IBD as the underlying disease; PG and
AS were more often treated when anti-TNF were initiated for
EIM, whereas EN and stomatitis were more often treated when
anti-TNF treatments were started for intestinal disease activity. No
anti-TNF therapy was initiated to treat underlying PSC. For de-
tails see Figure 1. As it is known that EIM can manifest under
anti-TNF therapy, we analyzed their ﬁrst presentation according
to the time point of anti-TNF introduction. In 11 patients, a total
TABLE 2. Frequency of Different EIMs According to IBD Subtype
UC (n ¼ 40) CD (n ¼ 165) IBD-U (n ¼ 6) Total (n ¼ 213)
Age at ﬁrst EIM 36.8 (17.7 to 58.1) 35.2 (4.5 to 66.0) 32.8 (27.7–37.9) 35.3 (4.5 to 66.0)
Duration from IBD to EIM 4.9 (20.4 to 16.8) 3.9 (217.7 to 34.2) 4.0 (0.0–8.0) 4.4 (217.7 to 34.2)
No. of EIM, n (%)
1 27 (67.5) 88 (53.3) 6 (100.0) 122 (57.3)
2 11 (27.5) 53 (32.1) 0 (0.0) 65 (30.5)
3 1 (2.5) 9 (5.5) 0 (0.0) 10 (4.7)
4 1 (2.5) 6 (3.6) 0 (0.0) 7 (3.3)
5 0 (0.0) 9 (5.5) 0 (0.0) 9 (4.2)
EIM, n (%)
Arthritis 24 (60.0) 131 (79.4) 5 (83.3) 161 (75.6)
Uveitis 4 (10.0) 29 (17.6) 0 (0.0) 33 (15.5)
PG 2 (5.0) 9 (5.5) 0 (0.0) 11 (5.2)
EN 7 (17.5) 18 (10.9) 0 (0.0) 26 (12.2)
Stomatitis 4 (10.0) 46 (27.9) 0 (0.0) 50 (23.5)
AS 9 (22.5) 35 (21.2) 1 (16.7) 46 (21.6)
PSC 4 (10.0) 6 (3.6) 0 (0.0) 10 (4.7)
Psoriasis 1 (2.5) 7 (4.2) 0 (0.0) 8 (3.8)
IBD subtype of 2 patients unknown.
IBD-U, IBD unclassiﬁed.
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of 14 different EIMs developed under anti-TNF treatment: 4 pa-
tients suffered from newly diagnosed peripheral arthritis, 1 patient
had peripheral arthritis and AS, 3 patients suffered from PG, 1
patient from aphthous stomatitis, 1 patient from psoriasis, and 1
patient from peripheral arthritis, uveitis, and aphthous stomatitis.
Most (11/14, 76.9% of EIM) was observed under inﬂiximab, 2
under adalimumab, and 1 under certolizumab pegol. Most of the
EIM improved during continuation of anti-TNF treatment
(64.3%), whereas only in 1 patient a clinical worsening (PG)
was documented. In the majority (94.4%), EIM did not manifest
under anti-TNF treatment.
Clinical Evolution of EIM Under Anti-
TNF Treatment
We assessed the clinical evolution of EIM under anti-TNF
treatment. In 71.8% (163/227) of all anti-TNF therapies, patients
demonstrated a clinical improvement of the underlying EIM. In
26.4% (60/227), no response was observed, whereas in only 1.8%
(4/227) a worsening of EIM was seen under anti-TNF treatment.
For the remaining 72 anti-TNF treatments, the exact evolution of
EIM could not be identiﬁed. Inﬂiximab showed an improvement
rate of 74%, adalimumab of 70%, and certolizumab pegol of 56%.
The difference between intravenous (inﬂiximab) and subcutane-
ous anti-TNF agents (adalimumab, certolizumab pegol) was only
slight, and not statistically signiﬁcant. For details see Figure 2.
Anti-TNF agent did not predict treatment outcome in a logistic
regression model (see Supplementary Table 1, Supplemental Dig-
ital Content 1, http://links.lww.com/IBD/B491). The best
response rates were reported for psoriasis (6/6, 100%), EN
(8/10, 80%), aphthous stomatitis (25/32, 78.1%), peripheral arthri-
tis (116/158, 73.4%), and uveitis (18/25, 72.0%). Only PG
showed a response rate of less than 60%. If only those 93 patients
who were actually treated for EIM (92 patients for EIM alone, 1
patient for EIM and IBD) were included in outcome analysis,
peripheral arthritis and uveitis showed even higher rates of
improvement. For details see Figures 3 and 4. There was no
difference in anti-TNF response when patients with concomitant
immunosuppressive treatment were compared with those without
(70.2% versus 73.6%, P ¼ 0.577). Moreover, concomitant immu-
nosuppressive treatment was no predictor for anti-TNF outcome
in a logistic regression model (for details see Supplementary
Table 1, Supplemental Digital Content 1, http://links.lww.com/
IBD/B491). Use of anti-TNF and overall anti-TNF response rates
of EIM associated with IBD activity and EIM not associated with
intestinal disease were comparable; overall response rates were
74.3% and 65.5%, respectively, P ¼ 0.165 (see Supplementary
FIGURE 1. Frequency of treated EIM according to anti-TNF indication. Y-axis depicts the percentage of patients treated for each individual EIM.
X-axis shows individual EIM according to whether underlying EIM or IBD was treated. As some patients were treated for several EIMs, the sum may
exceed 100%. Patients who were treated with anti-TNF for EIM had signiﬁcantly more often AS and PG. In contrast, patients who received anti-TNF
for intestinal disease activity more often had stomatitis and EN. No anti-TNF treatment was initiated to treat PSC.
FIGURE 2. Overall outcome of anti-TNF treatment. Inﬂiximab (IFX)
showed an improvement rate of 74%, adalimumab (ADA) of 70%, and
certolizumab pegol (CZP) of 56%.
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Table 2, Supplemental Digital Content 1, http://links.lww.com/
IBD/B491). Furthermore, IBD activity did not predict anti-TNF
outcome in a logistic regression model (see Supplementary
Table 1, Supplemental Digital Content 1, http://links.lww.com/
IBD/B491). Indeed, the only predictor for negative anti-TNF
response was the presence of UC/IBD unclassiﬁed, even in a mul-
tivariate analysis corrected for age, sex, and previous anti-TNF
use (odds ratio 0.337 [0.144–0.793], P ¼ 0.013). For details see
Supplementary Table 1, Supplemental Digital Content 1, http://
links.lww.com/IBD/B491.
DISCUSSION
In this retrospective analysis of the Swiss IBD Cohort
Study, we report on the use of anti-TNF agents in IBD patients
with EIM in Switzerland and EIM evolution under such therapy.
More than half of the patients presenting with EIM were treated
with anti-TNF. The presence of EIM was signiﬁcantly associated
with the use of anti-TNF. In more than 40% of patients, anti-TNF
treatments were started for the purpose of treating underlying
EIM. Response rates to anti-TNF were generally good with
overall improvement rates of more than 70%. Best response rates
were seen for psoriasis, aphthous stomatitis, uveitis, and periph-
eral arthritis.
Peripheral arthritis was the most frequently observed EIM,
which was treated with anti-TNF, followed by aphthous stoma-
titis, AS, uveitis, and skin manifestations (such as EN, PG, and
psoriasis). The order of EIM frequency was consistent with
a previous study from the SIBDCS, which analyzed the total
frequency of EIM in the Swiss cohort.10 Thus, the most frequent
EIMs are also the ones which are most frequently treated with
anti-TNF. Psoriasis for example, which is the least frequently
occurring EIM in the Swiss cohort (1.5% according to Vavricka
et al10), was also the least frequently anti-TNF-treated EIM. How-
ever, the low prevalence of psoriasis contrasts other EIM studies
such as the one by Yates et al32 who showed a prevalence of
11.2% in CD and 5.7% in patients with UC, respectively. Despite
the limited evidence for anti-TNF agents in EIM management,
anti-TNF treatments were started in more than 40% to treat under-
lying EIM rather than intestinal disease activity. When anti-TNF
was started for EIM, order of frequency of treated EIM was sig-
niﬁcantly different compared with the condition, when therapy
was initiated for IBD: PG and AS were signiﬁcantly more often
treated when anti-TNF was started for EIM, whereas anti-TNF
therapy was rarely initiated for EN or stomatitis. This ﬁnding
nicely illustrates the concept of IBD dependence of some, but
not all EIMs. In addition, relative frequency of PG treatment is
consistent with the fact that the evidence for inﬂiximab’s efﬁcacy
in EIM management is the strongest for PG.26 No treatment was
started for PSC, which may be due to very contradictory data
hitherto.33
Although there is some evidence to support anti-TNF
treatment in peripheral arthritis, AS, and PG,20,26,34 data for most
EIM are limited and are partially based on small case series or
reports of severe and difﬁcult-to-treat patients.21,35,36 Hence, our
ﬁnding of an overall response rate of more than 70% advances our
knowledge about the efﬁcacy of anti-TNF. Anti-TNF outcome
was best for psoriasis, aphthous stomatitis, uveitis, and peripheral
arthritis in those patients who were treated for EIM rather than
IBD. Response rates for uveitis and arthritis were comparable
with those very recently published in a comprehensive review
by Peyrin-Biroulet et al, although our study population relevantly
exceeds the number of patients in the studied trials (response for
uveitis 1/1 and 2/2, response for arthritis 19/31 and 8/10).
Response rates for AS were slightly higher in the mentioned
review (response for AS 5/7, response for inﬂammatory back pain
7/11), although our patient numbers again were higher. Response
rates for stomatitis were comparable. If we look at all patients
with stomatitis being treated with anti-TNF, our study population
again relevantly exceeds patient number studied in the systematic
review (3 versus 33).31 Excellent response rates for psoriasis are
consistent with previous studies showing successful use of anti-
TNF in psoriasis management.37,38 In contrast to the mentioned
review by Peyrin-Biroulet, where no or only minimal evidence for
FIGURE 3. Overall anti-TNF response rates (213 patients). Response
rates were best for psoriasis (6/6, 100%), EN (8/10, 80%), and stomatitis
(25/32, 78.1%).
FIGURE 4. Anti-TNF response rates in those patients treated for EIM
(93 patients, 113 EIMs). Psoriasis and stomatitis showed response rates
of 100%; however, both were excluded from analysis because of the
low number (n ¼ 1).
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other biological agents such as certolizumab was found, we herein
report on 43 cases treated with certolizumab pegol showing good
clinical response rates, which were not signiﬁcantly different from
those of inﬂiximab or adalimumab.
Our study has several strengths and some limitations as well.
With 213 patients receiving a total of 299 anti-TNF treatments for
355 EIM, it represents one of the largest analyses of EIM
management. Questionnaires evaluating EIM and anti-TNF treat-
ment outcome were physician and patient based and therefore less
prone to underreporting. However, we used a retrospective uncon-
trolled, noninterventional study design, which limits interpretation
of treatment outcome. Assessment of anti-TNF outcome was not
standardized and based on physician’s interpretation of patient
history, clinical ﬁndings, and laboratory parameters (in the
case of PSC) only. Furthermore, as the SIBDCS is not strictly
population based, a selection bias may be present. A clear limitation
of our analysis is that we did not include psoriasiform anti–TNF-
associated skin lesions, which is now a frequently reported
phenomenon.39 However, we included many patients with enroll-
ment and anti-TNF treatment before 2009; at that time, anti–TNF-
induced psoriasiform skin lesions were believed to be an extremely
rare event.40 In addition, only 13 cases have been identiﬁed at the
University Hospital Zurich between 2007 and 2013.41 The single
case of psoriasis under anti-TNF treatment in our analysis is rather
a coincidence than a misinterpreted anti–TNF-induced skin lesion
given the fact that improvement was observed with continuation of
anti-TNF treatment. Because of the retrospective nature, it was not
possible to clearly distinguish the 14 EIMs that occurred under anti-
TNF treatment from anti-TNF side effects. Neither antidrug anti-
bodies nor drug levels were checked in these patients. Furthermore,
a nonnegligible proportion of patients received concomitant immu-
nomodulators or steroids, so there may be an additional effect.
However, similar results were seen, when those patients with con-
comitant therapy were excluded from analysis. In addition, con-
comitant immunosuppressive treatment did not predict anti-TNF
outcome in logistic regression model.
In conclusion, anti-TNF agents were frequently used in
patients with EIM and were started in more than 40% to treat EIM
rather than IBD. Given the good response rates, the anti-TNF
agents such as inﬂiximab, adalimumab, and certolizumab pegol
seem to be a valuable option in the treatment of EIM, whereas
appearance of EIM as a side effect does not seem to be a source of
considerable concern. In any case, to clearly establish the role of
TNF inhibitors for treatment of EIM, randomized controlled trials
are needed.
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